• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    CNO Financial Group Reports Second Quarter 2024 Results

    7/29/24 4:15:00 PM ET
    $CNO
    Accident &Health Insurance
    Finance
    Get the next $CNO alert in real time by email

    Earnings per share up 66%; Operating earnings per share up 94%

    CARMEL, Ind., July 29, 2024 /PRNewswire/ -- CNO Financial Group, Inc. (NYSE:CNO) today reported net income of $116.3 million, or $1.06 per diluted share, in 2Q24 compared to $73.7 million, or $0.64 per diluted share, in 2Q23. Net operating income (1) was $114.6 million, or $1.05 per diluted share, in 2Q24 compared to $62.3 million, or $0.54 per diluted share, in 2Q23.

    "CNO delivered excellent earnings and operating performance across the board, led by continued sales momentum, a growing agent force, and strong underwriting margins and net investment income in the quarter," said Gary C. Bhojwani, chief executive officer. "Sales grew for the eighth consecutive quarter, illustrating the strength of our broad product offerings and diverse distribution model to serve the middle-income market."

    "All of our Growth Scorecard performance metrics were up in the quarter. Our capital position remained strong as we increased book value per share, while returning more than $77 million to shareholders."

    "CNO enters the second half of the year with consistent sales momentum and continuing favorable macro trends. We remain well-positioned to deliver sustainable profitable growth and long-term shareholder value."

    Second Quarter 2024 Highlights (as compared to the corresponding period in the prior year where applicable)

    • Total new annualized premiums ("NAP") (4) up 4%; Worksite Division NAP up 18%; Consumer Division NAP up 2%
    • Medicare Supplement NAP up 16%; Medicare Advantage policies sold up 78%
    • Annuity collected premiums up 9%; Policyholder and client assets up 9%
    • Returned $77.2 million to shareholders
    • Book value per share was $22.80, up 30%; book value per diluted share, excluding accumulated other comprehensive loss, (2) was $36.00, up 11%
    • Return on equity ("ROE") of 19.9%; operating ROE, as adjusted, (5) of 11.2%
    • Raising full-year guidance on earnings and cash flow

     

    FINANCIAL SUMMARY

    Quarter End

    (Amounts in millions, except per share data)

    (Unaudited)

     

    Net operating income, a non-GAAP(a) financial measure, is used consistently by CNO's management to evaluate the operating performance of the Company and is a measure commonly used in the life insurance industry.  It differs from net income primarily because it excludes certain non-operating items such as net realized investment gains (losses) from sales and change in the allowance for credit losses, changes in fair values of embedded derivatives and market risk benefits and the liability for a deferred compensation plan, and certain significant and unusual items included in net income.  Management believes an analysis of net operating income is important in understanding the profitability and operating trends of the Company's business.  Net income is the most directly comparable GAAP measure.





    Per diluted share

















    Quarter ended



    Quarter ended



    June 30,



    June 30,



    2024





    2023



    % change



    2024





    2023



    % change





























    Income from insurance products (b)

    $           1.10





    $            0.64



    72



    $     120.5





    $      73.7



    64

    Fee income

    0.01





    —



    n/m



    0.8





    0.6



    33

    Investment income not allocated to product lines (c)

    0.41





    0.24



    71



    44.8





    28.0



    60

    Expenses not allocated to product lines

    (0.16)





    (0.18)



    (11)



    (17.5)





    (21.1)



    (17)

    Operating earnings before taxes

    1.36





    0.70







    148.6





    81.2





    Income tax expense on operating income

    (0.31)





    (0.16)



    94



    (34.0)





    (18.9)



    80

    Net operating income (1)

    1.05





    0.54



    94



    114.6





    62.3



    84

    Net realized investment losses from sales and change in allowance for credit losses

    (0.20)





    (0.27)







    (21.9)





    (31.3)





    Net change in market value of investments recognized in earnings

    0.04





    (0.04)







    4.7





    (4.0)





    Changes in fair value of embedded derivative liabilities and market risk benefits

    0.15





    0.44







    16.8





    50.4





    Other

    0.02





    —







    2.4





    (0.2)





    Non-operating income before taxes

    0.01





    0.13







    2.0





    14.9





    Income tax expense on non-operating income

    —





    (0.03)







    (0.3)





    (3.5)





    Net non-operating income

    0.01





    0.10







    1.7





    11.4





    Net income

    $           1.06





    $            0.64







    $     116.3





    $      73.7

































    Weighted average diluted shares outstanding

    109.3





    115.6



















    n/m - not meaningful

    ____________________

    (a)  

    GAAP is defined as accounting principles generally accepted in the United States of America.

    (b)  

    Income from insurance products is the sum of the insurance margins of the annuity, health and life product lines, less expenses allocated to the insurance product lines.  It excludes the income from our fee income business, investment income not allocated to product lines, net expenses not allocated to product lines (primarily holding company expenses) and income taxes.  Insurance margin is management's measure of the profitability of its annuity, health and life segments' performance and consists of insurance policy income plus allocated investment income less insurance policy benefits, interest credited, commissions, advertising expense and amortization of acquisition costs.

    (c)  

    Investment income not allocated to product lines represents net investment income less: (i) equity returns credited to policyholder account balances; (ii) the investment income allocated to our product lines; (iii) interest expense on notes payable, investment borrowings and financing arrangements; (iv) expenses related to the funding agreement-backed notes ("FABN") program; and (v) certain expenses related to benefit plans that are offset by special-purpose investment income; plus (vi) the impact of annual option forfeitures related to fixed indexed annuity surrenders.

     

    FINANCIAL SUMMARY (continued)

    Management vs. GAAP Measures

    (Dollars in millions, except per share data)

    (Unaudited)

     

    Shareholders' equity, excluding accumulated other comprehensive income (loss), and book value per share, excluding accumulated other comprehensive income (loss), are non-GAAP measures that are utilized by management to view the business without the effect of accumulated other comprehensive income (loss) which is primarily attributable to fluctuations in interest rates associated with fixed maturities, available for sale.  Management views the business in this manner because the Company has the ability and generally, the intent, to hold investments to maturity and meaningful trends can be more easily identified without the fluctuations.  In addition, shareholders' equity excludes net operating loss carryforwards in our non-GAAP return on equity measures as such assets are not discounted and, accordingly, will not provide a return to shareholders until after it is realized as a reduction to taxes that would otherwise be paid.  Management believes that excluding this value from the equity component of this measure enhances the understanding of the effect these non-discounted assets have on operating returns.













    Quarter ended











    June 30,











    2024



    2023

















    Trailing twelve months return on equity (a)









    19.9 %



    14.8 %

    Trailing twelve months operating return on equity, excluding accumulated other comprehensive income (loss)

    and net operating loss carryforwards (a non-GAAP financial measure) (5)









    11.2 %



    8.0 %

    Trailing twelve months operating return, excluding significant items, on equity, excluding accumulated other

    comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) (5)









    10.0 %



    8.0 %

































    Shareholders' equity









    $     2,428.9



    $    1,995.8

    Accumulated other comprehensive loss









    1,464.3



    1,733.5

















    Shareholders' equity, excluding accumulated other comprehensive loss









    3,893.2



    3,729.3

    Net operating loss carryforwards









    (296.5)



    (126.3)

    Shareholders' equity, excluding accumulated other comprehensive loss and net operating loss carryforwards









    $     3,596.7



    $    3,603.0

















    Book value per diluted share









    $        22.46



    $       17.31

    Accumulated other comprehensive loss









    13.54



    15.03

















    Book value per diluted share, excluding accumulated other comprehensive loss (a non-GAAP financial

    measure) (2)









    $        36.00



    $       32.34

    ____________________

    (a)  Calculated using average shareholders' equity for the measurement period.

    Non-Operating Items

    Net investment losses in 2Q24 were $21.9 million net of a reduction in the allowance for credit losses of $4.1 million. Net investment losses in 2Q23 were $31.3 million including an increase in the allowance for credit losses of $9.9 million.

    During 2Q24 and 2Q23, we recognized an increase (decrease) in earnings of $4.7 million and $(4.0) million, respectively, due to the net change in market value of investments.

    During 2Q24 and 2Q23, we recognized an increase in earnings of $16.8 million and $50.4 million, respectively, resulting from changes in the estimated fair value of embedded derivative liabilities and market risk benefits related to our fixed indexed annuities.  Such amounts include the impacts of changes in market interest rates and equity impacts used to determine the estimated fair values of the embedded derivatives and market risk benefits.

    In 2Q24, other non-operating items included an increase in earnings of $3.5 million for the mark-to-market change in the agent deferred compensation plan liability which was impacted by changes in the underlying actuarial assumptions used to value the liability. We recognize the mark-to-market change in the estimated value of this liability through earnings as assumptions change.

    INVESTMENT PORTFOLIO

    (Dollars in millions)



    Fixed maturities, available for sale, at amortized cost by asset class as of June 30, 2024 are as follows:





    Investment

    grade



    Below

    investment

    grade



    Total

    Corporate securities

    $     12,849.3



    $          601.4



    $     13,450.7

    Certificates of deposit

    470.2



    —



    470.2

    United States Treasury securities and obligations of the United States government and agencies

    278.6



    —



    278.6

    States and political subdivisions

    3,182.9



    9.6



    3,192.5

    Foreign governments

    101.1



    —



    101.1

    Asset-backed securities

    1,448.4



    103.8



    1,552.2

    Agency residential mortgage-backed securities

    787.3



    —



    787.3

    Non-agency residential mortgage-backed securities

    1,231.7



    435.5

    (a)

    1,667.2

    Collateralized loan obligations

    1,227.6



    —



    1,227.6

    Commercial mortgage-backed securities

    2,290.1



    88.6



    2,378.7













    Total

    $     23,867.2



    $       1,238.9



    $     25,106.1

    ____________________

    (a)     

    Certain structured securities rated below investment grade by Nationally Recognized Statistical Rating Organizations may be assigned a NAIC 1 or NAIC 2 designation based on the cost basis of the security relative to estimated recoverable amounts as determined by the National Association of Insurance Commissioners (NAIC).

    The fair value of CNO's available for sale fixed maturity portfolio was $22.6 billion compared with an amortized cost of $25.1 billion.  Net unrealized losses were comprised of gross unrealized gains of $113.2 million and gross unrealized losses of $2,561.6 million.  The allowance for credit losses was $39.8 million at June 30, 2024.

    Statutory (based on non-GAAP measures) and GAAP Capital Information

    The consolidated statutory risk-based capital ratio of our U.S. based insurance subsidiaries was estimated at 394% at June 30, 2024, reflecting estimated 2Q24 statutory operating earnings of $28 million (and $24 million in the first six months of 2024) and the payment of insurance company dividends (net of capital contributions) to the holding company of $29.7 million during 2Q24 (and $73.0 million (net of capital contributions) in the first six months of 2024).

    During 2Q24, we repurchased $60.0 million of common stock under our securities repurchase program (including $1.1 million of repurchases settled in 3Q24).  We repurchased 2.2 million common shares at an average cost of $27.61 per share.  As of June 30, 2024, we had 106.5 million shares outstanding and had authority to repurchase up to an additional $421.8 million of our common stock.  During 2Q24, dividends paid on common stock totaled $17.2 million.

    Unrestricted cash and investments held by our holding company were $429 million at June 30, 2024, compared to $256 million at December 31, 2023.  In addition, the holding company has invested $500 million of the proceeds from the previously announced issuance of $700.0 million of 6.450% senior notes due 2034 (the "2034 Notes") primarily into certificates of deposit which are expected to be used for the repayment of $500.0 million of 5.250% senior notes due May 2025 (the "2025 Notes").

    Book value per common share was $22.80 at June 30, 2024 compared to $20.26 at December 31, 2023.  Book value per diluted share, excluding accumulated other comprehensive income (loss) (2), was $36.00 at June 30, 2024, compared to $33.94 at December 31, 2023. 

    The debt-to-capital ratio was 43.0% and 34.0% at June 30, 2024 and December 31, 2023, respectively.  Our debt-to-total capital ratio, excluding accumulated other comprehensive income (loss) (3) was 32.0% and 23.1% at June 30, 2024 and December 31, 2023, respectively. Such debt-to-total capital ratios reflect the issuance of the 2034 Notes in May 2024.  At June 30, 2024, adjusting for the expected repayment of the 2025 Notes, the debt-to-total capital ratio would have been 35.4% and the debt-to-total capital ratio, excluding accumulated other comprehensive income (loss), would have been 25.5%.

    Return on equity for the trailing four quarters ended June 30, 2024 and 2023, was 19.9% and 14.8%, respectively.  Operating return, excluding significant items, on equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (5) for the trailing four quarters ended June 30, 2024 and 2023, was 10.0% and 8.0%, respectively.

    In this news release, CNO includes non-GAAP measures to enhance investors' understanding of management's view of the business.  The non-GAAP measures are not a substitute for GAAP, but rather a supplement to increase transparency by providing a broader perspective.  CNO's definitions of non-GAAP measures may differ from other companies' definitions.  More detailed information including various GAAP and non-GAAP measurements are located at CNOinc.com in the Investors section under SEC Filings.

    CAUTION REGARDING FORWARD-LOOKING STATEMENTS:

    This press release may contain forward-looking statements within the meaning of federal securities laws.  These prospective statements reflect management's current expectations, but are not guarantees of future performance.  Accordingly, please refer to CNO's cautionary statement regarding forward-looking statements, and the business environment in which the Company operates, contained in the Company's Form 10-K for the year ended December 31, 2023 and any subsequent Form 10-Q or Form 10-K on file with the Securities and Exchange Commission and on the Company's website at CNOinc.com in the Investors section.  CNO specifically disclaims any obligation to update or revise any forward-looking statement because of new information, future developments or otherwise.

    EARNINGS RELEASE CONFERENCE CALL WEBCAST:

    The Company will host a conference call to discuss results on July 30, 2024 at 11:00 a.m. Eastern Time.  During the call, we will be referring to a presentation that will be available at the Investors section of the company's website.

    To participate by dial-in, please register at https://www.netroadshow.com/events/login?show=51d949bc&confId=68394. Upon registering, you will be provided with call details and a registrant ID used to track attendance on the conference call. Reminders will also be sent to registered participants via email.

    For those investors who prefer to listen to the call online, we will be broadcasting the call live via webcast.  The event can be accessed through the Investors section of the company's website: ir.CNOinc.com.  Participants should go to the website at least 15 minutes before the event to register and download any necessary audio software.

    ABOUT CNO FINANCIAL GROUP

    CNO Financial Group, Inc. (NYSE:CNO) secures the future of middle-income America.  CNO provides life and health insurance, annuities, financial services, and workforce benefits solutions through our family of brands, including Bankers Life, Colonial Penn, Optavise and Washington National.  Our customers work hard to save for the future, and we help protect their health, income, and retirement needs with 3.2 million policies and $36 billion in total assets. Our 3,500 associates, 4,800 exclusive agents and more than 5,000 independent partner agents guide individuals, families, and businesses through a lifetime of financial decisions. For more information, visit CNOinc.com.

     

    CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

    CONSOLIDATED BALANCE SHEET

    (Dollars in millions)

    (unaudited)





    June 30,

    2024



    December 31,

    2023

    ASSETS







    Investments:







    Fixed maturities, available for sale, at fair value (net of allowance for credit losses: June 30,

    2024 - $39.8 and December 31, 2023 - $42.9; amortized cost: June 30, 2024 - $25,106.1 and

    December 31, 2023 - $23,699.2)

    $           22,617.9



    $           21,506.2

    Equity securities at fair value

    117.7



    96.9

    Mortgage loans (net of allowance for credit losses: June 30, 2024 - $13.2 and December 31,

    2023 - $15.4)

    2,176.0



    2,064.1

    Policy loans

    131.3



    128.5

    Trading securities

    207.8



    222.7

    Investments held by variable interest entities (net of allowance for credit losses: June 30, 2024 -

    $2.8 and December 31, 2023 - $3.1; amortized cost: June 30, 2024 - $440.6 and December 31,

    2023 - $787.6)

    425.5



    768.6

    Other invested assets

    1,554.0



    1,353.4

    Total investments

    27,230.2



    26,140.4

    Cash and cash equivalents - unrestricted

    878.8



    774.5

    Cash and cash equivalents held by variable interest entities

    113.3



    114.5

    Accrued investment income

    262.5



    251.5

    Present value of future profits

    170.4



    180.7

    Deferred acquisition costs

    2,047.2



    1,944.4

    Reinsurance receivables (net of allowance for credit losses: June 30, 2024 - $3.0 and

    December 31, 2023 - $3.0)

    3,910.9



    4,040.7

    Market risk benefit asset

    84.5



    75.4

    Income tax assets, net

    882.8



    936.2

    Assets held in separate accounts

    3.2



    3.1

    Other assets

    706.4



    641.1

    Total assets

    $           36,290.2



    $           35,102.5

    LIABILITIES AND SHAREHOLDERS' EQUITY







    Liabilities:







    Liabilities for insurance products:







    Policyholder account balances

    $           16,637.9



    $           15,667.8

    Future policy benefits

    11,479.4



    11,928.2

    Market risk benefit liability

    3.2



    7.4

    Liability for life insurance policy claims

    59.6



    62.1

    Unearned and advanced premiums

    220.9



    218.9

    Liabilities related to separate accounts

    3.2



    3.1

    Other liabilities

    934.4



    848.8

    Investment borrowings

    2,189.0



    2,189.3

    Borrowings related to variable interest entities

    501.4



    820.8

    Notes payable – direct corporate obligations

    1,832.3



    1,140.5

    Total liabilities

    33,861.3



    32,886.9

    Commitments and Contingencies







    Shareholders' equity:







    Common stock ($0.01 par value, 8,000,000,000 shares authorized, shares issued and

    outstanding: June 30, 2024 – 106,513,566; December 31, 2023 – 109,357,540)

    1.1



    1.1

    Additional paid-in capital

    1,797.6



    1,891.5

    Accumulated other comprehensive loss

    (1,464.3)



    (1,576.8)

    Retained earnings

    2,094.5



    1,899.8

    Total shareholders' equity

    2,428.9



    2,215.6

    Total liabilities and shareholders' equity

    $           36,290.2



    $           35,102.5

     

    CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

    CONSOLIDATED STATEMENT OF OPERATIONS

    (Dollars in millions, except per share data)

    (unaudited)





    Three months ended



    Six months ended



    June 30,



    June 30,



    2024



    2023



    2024



    2023

    Revenues:















    Insurance policy income

    $              641.5



    $             628.3



    $          1,269.9



    $           1,253.8

    Net investment income:















    General account assets

    351.7



    308.1



    653.6



    600.3

    Policyholder and other special-purpose portfolios

    57.4



    91.6



    224.7



    142.4

    Investment gains (losses):















    Realized investment losses

    (26.3)



    (21.8)



    (36.3)



    (36.4)

    Other investment gains (losses)

    9.1



    (13.5)



    26.9



    (13.5)

    Total investment losses

    (17.2)



    (35.3)



    (9.4)



    (49.9)

    Fee revenue and other income

    32.8



    30.1



    83.9



    82.2

    Total revenues

    1,066.2



    1,022.8



    2,222.7



    2,028.8

    Benefits and expenses:















    Insurance policy benefits

    568.8



    565.9



    1,200.2



    1,175.6

    Liability for future policy benefits remeasurement (gain) loss

    (30.0)



    8.3



    (36.4)



    8.9

    Change in fair value of market risk benefits

    (0.2)



    (17.6)



    (13.9)



    (2.8)

    Interest expense

    64.2



    57.6



    124.4



    112.3

    Amortization of deferred acquisition costs and present value of future

    profits 

    61.4



    56.0



    121.9



    111.5

    Other operating costs and expenses

    251.4



    256.5



    529.7



    528.2

    Total benefits and expenses

    915.6



    926.7



    1,925.9



    1,933.7

    Income before income taxes

    150.6



    96.1



    296.8



    95.1

    Income tax expense

    34.3



    22.4



    68.2



    22.2

    Net income

    $              116.3



    $               73.7



    $             228.6



    $               72.9

    Earnings per common share:















    Basic:















    Weighted average shares outstanding

    107,731,000



    114,273,000



    108,347,000



    114,409,000

    Net income

    $                1.08



    $                 .64



    $               2.11



    $                 .64

    Diluted:















    Weighted average shares outstanding

    109,258,000



    115,650,000



    110,052,000



    116,189,000

    Net income

    $                1.06



    $                 .64



    $               2.08



    $                 .63





    NOTES



    (1)

    Management believes that an analysis of net income applicable to common stock before: (i) net realized investment gains or losses from sales, impairments and the change in allowance for credit losses, net of taxes; (ii) net change in market value of investments recognized in earnings, net of taxes; (iii) changes in fair value of embedded derivative liabilities and market risk benefits related to our fixed indexed annuities, net of taxes; (iv) fair value changes related to the agent deferred compensation plan, net of taxes; (v) loss related to reinsurance transaction, net of taxes; (vi) loss on extinguishment of debt, net of taxes; (vii) changes in the valuation allowance for deferred tax assets and other tax items; and (viii) other non-operating items consisting primarily of earnings attributable to variable interest entities, net of taxes ("net operating income," a non-GAAP financial measure) is important to evaluate the financial performance of the company, and is a key measure commonly used in the life insurance industry.  Management uses this measure to evaluate performance because the items excluded from net operating income can be affected by events that are unrelated to the company's underlying fundamentals.  A reconciliation of net operating income to net income applicable to common stock is provided in the table on page 2.  Additional information concerning this non-GAAP measure is included in our periodic filings with the Securities and Exchange Commission that are available in the "Investors - SEC Filings" section of CNO's website, CNOinc.com.

    (2)

    Book value per diluted share reflects the potential dilution that could occur if outstanding stock options were exercised and restricted stock and performance units were vested.  The dilution from options, restricted shares and performance units is calculated using the treasury stock method.  Under this method, we assume the proceeds from the exercise of the options (or the unrecognized compensation expense with respect to restricted stock and performance units) will be used to purchase shares of our common stock at the closing market price on the last day of the period.  In addition, the calculation of this non-GAAP measure differs from the corresponding GAAP measure because accumulated other comprehensive income (loss) has been excluded from the value of capital used to determine this measure.  Management believes this non-GAAP measure is useful because it removes the volatility that arises from changes in the unrealized appreciation (depreciation) of our investments.

    (3)

    The calculation of this non-GAAP measure differs from the corresponding GAAP measure because accumulated other comprehensive income (loss) has been excluded from the value of capital used to determine this measure.  Management believes this non-GAAP measure is useful because it removes the volatility that arises from changes in the unrealized appreciation (depreciation) of our investments.

    (4)

    Measured by new annualized premiums for life and health products, which includes 10% of single premium whole life deposits and 100% of all other premiums (excluding annuities).  Sales of third-party products are excluded.

    (5)

    The following summarizes the calculations of: (i) operating return on equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure); (ii) operating return, excluding significant items, on equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure); and (iii) return on equity are as follows (dollars in millions):

     







    Trailing twelve months ended







    2Q24



    2Q23

    Net operating income

    $        407.3



    $     281.7













    Net operating income, excluding significant items

    $        364.0



    $     281.2













    Net income

    $        432.2



    $     286.8













    Average common equity, excluding accumulated other









    comprehensive income (loss) and net operating loss









    carryforwards (a non-GAAP financial measure)

    $     3,648.4



    $  3,519.3













    Average common shareholders' equity

    $     2,171.4



    $  1,931.5













    Operating return on equity, excluding accumulated other









    comprehensive income (loss) and net operating loss









    carryforwards (a non-GAAP financial measure)

    11.2 %



    8.0 %













    Operating return, excluding significant items, on equity, excluding









    accumulated other comprehensive income (loss) and net









    operating loss carryforwards (a non-GAAP financial measure)

    10.0 %



    8.0 %













    Return on equity

    19.9 %



    14.8 %

     

    The following summarizes: (i) net operating income; (ii) significant items; (iii) net operating income, excluding significant items; and (iv) net income (loss) (dollars in millions):

     

















    Net operating





















    Net operating



    income,





















    income,



    excluding







    Net













    excluding



    significant







    income -





    Net operating



    Significant



    significant



    items - trailing



    Net



    trailing





    income



    items



    items (a)



    four quarters



    income (loss)



    four quarters

    3Q22



    $                  77.9



    $                     —



    $                  77.9



    $                360.9



    $                175.9



    $                749.8

    4Q22



    82.9



    (0.5)

    (b)

    82.4



    342.5



    38.0



    630.6

    1Q23



    58.6



    —



    58.6



    336.6



    (0.8)



    446.4

    2Q23



    62.3



    —



    62.3



    281.2



    73.7



    286.8

    3Q23



    101.3



    (16.9)

    (c)

    84.4



    287.7



    167.3



    278.2

    4Q23



    133.9



    (26.4)

    (d)

    107.5



    312.8



    36.3



    276.5

    1Q24



    57.5



    —



    57.5



    311.7



    112.3



    389.6

    2Q24



    114.6



    —



    114.6



    364.0



    116.3



    432.2



























    (a)  See note (6) for additional information.



























    (b)  Comprised of $.7 million of the net favorable impact arising from our comprehensive annual actuarial review, net of tax expense of $.2 million.



























    (c)  Comprised of $21.7 million of legal recoveries, net of expenses and increased legal accruals, net of tax expense of $4.8 million.



























    (d)  Comprised of $33.9 million of the net favorable impact arising from our comprehensive annual actuarial review, net of tax expense of $7.5 million.

     

    A reconciliation of pre-tax operating earnings (a non-GAAP financial measure) to net income is as follows (dollars in millions):

     







    Twelve months ended







    2Q24



    2Q23

    Pre-tax operating earnings (a non-GAAP financial measure)

    $           525.3



    $            365.6

    Income tax expense

    (118.0)



    (83.9)

    Net operating income

    407.3



    281.7

    Non-operating items:







    Net realized investment losses from sales, impairments and change in allowance for credit

    losses

    (45.2)



    (71.9)

    Net change in market value of investments recognized in earnings

    16.7



    (31.9)

    Changes in fair value of embedded derivative liabilities and market risk benefits

    65.6



    99.5

    Fair value changes related to the agent deferred compensation plan

    —



    12.2

    Other

    (3.9)



    (2.0)

    Non-operating income before taxes

    33.2



    5.9

        Income tax expense on non-operating income

    (8.3)



    (0.8)

    Net non-operating income

    24.9



    5.1

    Net income

    $           432.2



    $            286.8













     

    A reconciliation of consolidated capital, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) to common shareholders' equity, is as follows (dollars in millions):

     







    1Q22



    2Q22



    3Q22



    4Q22

    Consolidated capital, excluding accumulated other comprehensive

















    income (loss) and net operating loss carryforwards

















    (a non-GAAP financial measure)

    $    3,141.7



    $    3,329.0



    $    3,510.3



    $    3,557.1

    Net operating loss carryforwards

    238.2



    214.7



    190.9



    169.0

    Accumulated other comprehensive loss

    (561.5)



    (1,415.8)



    (1,837.8)



    (1,957.3)

    Common shareholders' equity

    $    2,818.4



    $    2,127.9



    $    1,863.4



    $    1,768.8



























    1Q23



    2Q23



    3Q23



    4Q23

    Consolidated capital, excluding accumulated other comprehensive

















    income (loss) and net operating loss carryforwards

















    (a non-GAAP financial measure)

    $    3,543.8



    $    3,603.0



    $    3,744.2



    $    3,712.8

    Net operating loss carryforwards

    152.4



    126.3



    102.6



    79.6

    Accumulated other comprehensive loss

    (1,664.4)



    (1,733.5)



    (1,956.7)



    (1,576.8)

    Common shareholders' equity

    $    2,031.8



    $    1,995.8



    $    1,890.1



    $    2,215.6



























    1Q24



    2Q24









    Consolidated capital, excluding accumulated other comprehensive

















    income (loss) and net operating loss carryforwards

















    (a non-GAAP financial measure)

    $    3,536.8



    $    3,596.7









    Net operating loss carryforwards

    311.2



    296.5









    Accumulated other comprehensive loss

    (1,480.3)



    (1,464.3)









    Common shareholders' equity

    $    2,367.7



    $    2,428.9





























     

    A reconciliation of consolidated capital, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) to common shareholders' equity, is as follows (dollars in millions):

     







    Trailing four quarter average







    2Q24



    2Q23

    Consolidated capital, excluding accumulated other comprehensive









    income (loss) and net operating loss carryforwards









    (a non-GAAP financial measure)

    $        3,648.4



    $        3,519.3

    Net operating loss carryforwards

    176.2



    170.7

    Accumulated other comprehensive loss

    (1,653.2)



    (1,758.5)

    Common shareholders' equity

    $        2,171.4



    $        1,931.5

     

    (6)

    The tables below summarize the financial impact of significant items on our net operating income.  Management believes that identifying the impact of these items enhances the understanding of our operating results (dollars in millions, except per share data).

     





    Three months ended





    December 31, 2023





    Actual

    results



    Significant

    items



    Excluding

    significant

    items

    Insurance product margin













    Annuity margin



    $         63.6



    $        (12.9)

    (a)

    $          50.7

    Health margin



    146.4



    (22.3)

    (a)

    124.1

    Life margin



    64.6



    1.3

    (a)

    65.9

    Total insurance product margin



    274.6



    (33.9)



    240.7

    Allocated expenses



    (138.8)



    —



    (138.8)

    Income from insurance products



    135.8



    (33.9)



    101.9

    Fee income



    17.8



    —



    17.8

    Investment income not allocated to product lines



    38.3



    —



    38.3

    Expenses not allocated to product lines



    (19.8)



    —



    (19.8)

    Operating earnings before taxes



    172.1



    (33.9)



    138.2

    Income tax (expense) benefit on operating income



    (38.2)



    7.5



    (30.7)

    Net operating income



    $        133.9



    $        (26.4)



    $        107.5















    Net operating income per diluted share



    $         1.18



    $        (0.23)



    $          0.95

    ___________

    (a)    Comprised of $33.9 million of the net favorable impact arising from our comprehensive annual actuarial review.

     





    Three months ended





    September 30, 2023





    Actual

    results



    Significant

    items



    Excluding

    significant

    items

    Insurance product margin













    Annuity margin



    $         57.0



    $             —



    $          57.0

    Health margin



    123.2



    —



    123.2

    Life margin



    59.8



    —



    59.8

    Total insurance product margin



    240.0



    —



    240.0

    Allocated expenses



    (153.2)



    —



    (153.2)

    Income from insurance products



    86.8



    —



    86.8

    Fee income



    (2.9)



    —



    (2.9)

    Investment income not allocated to product lines



    38.4



    —



    38.4

    Expenses not allocated to product lines



    7.5



    (21.7)

    (a)

    (14.2)

    Operating earnings before taxes



    129.8



    (21.7)



    108.1

    Income tax (expense) benefit on operating income



    (28.5)



    4.8



    (23.7)

    Net operating income



    $        101.3



    $        (16.9)



    $          84.4















    Net operating income per diluted share



    $         0.88



    $        (0.14)



    $          0.74

    ___________

    (a)    Comprised of $21.7 million of legal recoveries, net of expenses and increased legal accruals.

     





    Three months ended





    December 31, 2022





    Actual

    results



    Significant

    items



    Excluding

    significant

    items

    Insurance product margin













    Annuity margin



    $         50.8



    $            3.2

    (a)

    $          54.0

    Health margin



    140.4



    (18.3)

    (a)

    122.1

    Life margin



    43.3



    14.4

    (a)

    57.7

    Total insurance product margin



    234.5



    (0.7)



    233.8

    Allocated expenses



    (149.1)



    —



    (149.1)

    Income from insurance products



    85.4



    (0.7)



    84.7

    Fee income



    9.2



    —



    9.2

    Investment income not allocated to product lines



    25.2



    —



    25.2

    Expenses not allocated to product lines



    (12.8)



    —



    (12.8)

    Operating earnings before taxes



    107.0



    (0.7)



    106.3

    Income tax (expense) benefit on operating income



    (24.1)



    0.2



    (23.9)

    Net operating income



    $         82.9



    $          (0.5)



    $          82.4















    Net operating income per diluted share



    $         0.71



    $             —



    $          0.71

    ___________

    (a)    Comprised of $0.7 million of the net favorable impact arising from our comprehensive annual actuarial review.

     

    Cision View original content:https://www.prnewswire.com/news-releases/cno-financial-group-reports-second-quarter-2024-results-302208833.html

    SOURCE CNO Financial Group

    Get the next $CNO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CNO

    DatePrice TargetRatingAnalyst
    1/23/2025$38.00Market Perform
    BMO Capital Markets
    4/16/2024$29.00Neutral → Overweight
    Piper Sandler
    1/4/2024$24.00 → $26.00In-line → Underperform
    Evercore ISI
    6/29/2023Mkt Perform
    Raymond James
    9/13/2022$25.00Outperform
    RBC Capital Mkts
    1/26/2022$25.00Hold
    Jefferies
    1/7/2022$27.00 → $28.00Equal-Weight
    Morgan Stanley
    1/5/2022$29.00 → $27.00Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $CNO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BMO Capital Markets initiated coverage on CNO Financial with a new price target

      BMO Capital Markets initiated coverage of CNO Financial with a rating of Market Perform and set a new price target of $38.00

      1/23/25 7:38:32 AM ET
      $CNO
      Accident &Health Insurance
      Finance
    • CNO Financial upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded CNO Financial from Neutral to Overweight and set a new price target of $29.00

      4/16/24 7:43:21 AM ET
      $CNO
      Accident &Health Insurance
      Finance
    • CNO Financial downgraded by Evercore ISI with a new price target

      Evercore ISI downgraded CNO Financial from In-line to Underperform and set a new price target of $26.00 from $24.00 previously

      1/4/24 8:13:08 AM ET
      $CNO
      Accident &Health Insurance
      Finance

    $CNO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CNO Financial Group Announces Voting Results from 2025 Annual Meeting of Shareholders

      CARMEL, Ind., May 8, 2025 /PRNewswire/ -- CNO Financial Group, Inc. (NYSE:CNO) announced that at the company's annual meeting held earlier today, its shareholders: Elected nine directors (Gary C. Bhojwani, Archie M. Brown, David B. Foss, Mary R. (Nina) Henderson, Adrianne B. Lee, Daniel R. Maurer, Chetlur S. Ragavan, Steven E. Shebik, and Jessica A. Turner) to each serve a one-year term expiring at next year's annual meeting.Approved, by non-binding advisory vote, the executive compensation of the company's named executive officers as disclosed in the proxy statement for the a

      5/8/25 4:15:00 PM ET
      $CNO
      Accident &Health Insurance
      Finance
    • CNO Financial Group Announces Increase of Quarterly Dividend to $0.17

      CARMEL, Ind., May 2, 2025 /PRNewswire/ -- CNO Financial Group, Inc. (NYSE:CNO) announced today that its Board of Directors has approved a $0.01 per share increase in its quarterly dividend, its thirteenth consecutive annual increase. The Board declared a quarterly cash dividend of $0.17 per share on the company's common shares. The dividend will be payable June 24, 2025, to shareholders of record at the close of business on June 10, 2025.  About CNO Financial Group CNO Financial Group, Inc. (NYSE:CNO) secures the future of middle-income America. CNO provides life and health in

      5/2/25 4:15:00 PM ET
      $CNO
      Accident &Health Insurance
      Finance
    • CNO Financial Group Reports First Quarter 2025 Results

      Solid start to 2025; Continuing track record of growth and improved profitability CARMEL, Ind., April 28, 2025 /PRNewswire/ -- CNO Financial Group, Inc. (NYSE:CNO) today reported net income of $13.7 million, or $0.13 per diluted share, in 1Q25 compared to $112.3 million or $1.01 per diluted share, in 1Q24. Non-economic accounting impacts due to market volatility reduced net income in 1Q25 and increased it in 1Q24. Net operating income,(1) which excludes these non-economic accounting impacts, was $81.1 million, or $0.79 per diluted share, in 1Q25 compared to $57.5 million, or $0.52 per diluted share, in 1Q24. Significant items(6) positively impacted both net income and net operating income(1)

      4/28/25 4:15:00 PM ET
      $CNO
      Accident &Health Insurance
      Finance

    $CNO
    Financials

    Live finance-specific insights

    See more
    • CNO Financial Group Announces Increase of Quarterly Dividend to $0.17

      CARMEL, Ind., May 2, 2025 /PRNewswire/ -- CNO Financial Group, Inc. (NYSE:CNO) announced today that its Board of Directors has approved a $0.01 per share increase in its quarterly dividend, its thirteenth consecutive annual increase. The Board declared a quarterly cash dividend of $0.17 per share on the company's common shares. The dividend will be payable June 24, 2025, to shareholders of record at the close of business on June 10, 2025.  About CNO Financial Group CNO Financial Group, Inc. (NYSE:CNO) secures the future of middle-income America. CNO provides life and health in

      5/2/25 4:15:00 PM ET
      $CNO
      Accident &Health Insurance
      Finance
    • CNO Financial Group Reports First Quarter 2025 Results

      Solid start to 2025; Continuing track record of growth and improved profitability CARMEL, Ind., April 28, 2025 /PRNewswire/ -- CNO Financial Group, Inc. (NYSE:CNO) today reported net income of $13.7 million, or $0.13 per diluted share, in 1Q25 compared to $112.3 million or $1.01 per diluted share, in 1Q24. Non-economic accounting impacts due to market volatility reduced net income in 1Q25 and increased it in 1Q24. Net operating income,(1) which excludes these non-economic accounting impacts, was $81.1 million, or $0.79 per diluted share, in 1Q25 compared to $57.5 million, or $0.52 per diluted share, in 1Q24. Significant items(6) positively impacted both net income and net operating income(1)

      4/28/25 4:15:00 PM ET
      $CNO
      Accident &Health Insurance
      Finance
    • CNO Financial Group to Release First Quarter Results on April 28, 2025

      CARMEL, Ind., April 14, 2025 /PRNewswire/ -- CNO Financial Group, Inc. (NYSE:CNO) will report results for the first quarter of 2025 after the market closes on Monday, April 28, 2025. The company will host a conference call to discuss results at 11:00 a.m. Eastern Time on Tuesday, April 29, 2025. Participate by Dial-InTo participate, please register here. Upon registering, you will be provided with call details and a registrant ID that is used to track attendance on the conference call. Reminders will also be sent to registered participants via email. Participate by WebcastFor

      4/14/25 4:15:00 PM ET
      $CNO
      Accident &Health Insurance
      Finance

    $CNO
    SEC Filings

    See more

    $CNO
    Leadership Updates

    Live Leadership Updates

    See more

    $CNO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $CNO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 10-Q filed by CNO Financial Group Inc.

      10-Q - CNO Financial Group, Inc. (0001224608) (Filer)

      5/7/25 4:21:36 PM ET
      $CNO
      Accident &Health Insurance
      Finance
    • CNO Financial Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CNO Financial Group, Inc. (0001224608) (Filer)

      4/28/25 4:17:18 PM ET
      $CNO
      Accident &Health Insurance
      Finance
    • SEC Form 144 filed by CNO Financial Group Inc.

      144 - CNO Financial Group, Inc. (0001224608) (Subject)

      4/3/25 4:01:38 PM ET
      $CNO
      Accident &Health Insurance
      Finance
    • CNO Financial Group Announces Voting Results from 2025 Annual Meeting of Shareholders

      CARMEL, Ind., May 8, 2025 /PRNewswire/ -- CNO Financial Group, Inc. (NYSE:CNO) announced that at the company's annual meeting held earlier today, its shareholders: Elected nine directors (Gary C. Bhojwani, Archie M. Brown, David B. Foss, Mary R. (Nina) Henderson, Adrianne B. Lee, Daniel R. Maurer, Chetlur S. Ragavan, Steven E. Shebik, and Jessica A. Turner) to each serve a one-year term expiring at next year's annual meeting.Approved, by non-binding advisory vote, the executive compensation of the company's named executive officers as disclosed in the proxy statement for the a

      5/8/25 4:15:00 PM ET
      $CNO
      Accident &Health Insurance
      Finance
    • CNO Financial Group Appoints Jess Turner to its Board of Directors

      CARMEL, Ind., Oct. 1, 2024 /PRNewswire/ -- CNO Financial Group, Inc. (NYSE:CNO) announced today that its board of directors has appointed Jess Turner as a director, effective immediately. Turner is Executive Vice President and Global Head of Open Banking and API at Mastercard (NYSE:MA), a global technology company in the payments industry, and is a member of its Management Committee. Turner's appointment increases the size of the CNO board to nine directors. "We are very pleased to welcome Jess to CNO's board of directors," said Board Chair Dan Maurer. "As a senior technology

      10/1/24 5:00:00 PM ET
      $CNO
      $MA
      Accident &Health Insurance
      Finance
      Business Services
      Consumer Discretionary
    • CNO Financial Group Announces Results from 2024 Annual Shareholder Meeting

      CARMEL, Ind., May 9, 2024 /PRNewswire/ -- CNO Financial Group, Inc. (NYSE:CNO) announced that at the company's annual meeting held earlier today, its shareholders: Elected eight directors (Gary C. Bhojwani, Archie M. Brown, David. B. Foss, Mary R. (Nina) Henderson, Adrianne B. Lee, Daniel R. Maurer, Chetlur S. Ragavan, and Steven E. Shebik) to each serve a one-year term expiring at next year's annual meeting.Approved, by non-binding advisory vote, the executive compensation of the company's named executive officers as disclosed in the proxy statement for the annual meeting.Rat

      5/9/24 4:15:00 PM ET
      $CNO
      Accident &Health Insurance
      Finance
    • SEC Form SC 13G/A filed by CNO Financial Group Inc. (Amendment)

      SC 13G/A - CNO Financial Group, Inc. (0001224608) (Subject)

      2/12/24 5:53:46 PM ET
      $CNO
      Accident &Health Insurance
      Finance
    • SEC Form SC 13G filed by CNO Financial Group Inc.

      SC 13G - CNO Financial Group, Inc. (0001224608) (Subject)

      2/9/24 11:33:46 AM ET
      $CNO
      Accident &Health Insurance
      Finance
    • SEC Form SC 13G/A filed by CNO Financial Group Inc. (Amendment)

      SC 13G/A - CNO Financial Group, Inc. (0001224608) (Subject)

      2/14/23 12:24:22 PM ET
      $CNO
      Accident &Health Insurance
      Finance
    • Director Henderson Mary R was granted 4,378 units of Common Stock, increasing direct ownership by 6% to 79,760 units (SEC Form 4)

      4 - CNO Financial Group, Inc. (0001224608) (Issuer)

      5/9/25 4:16:45 PM ET
      $CNO
      Accident &Health Insurance
      Finance
    • Director Maurer Dan was granted 7,403 shares, increasing direct ownership by 8% to 102,059 units (SEC Form 4)

      4 - CNO Financial Group, Inc. (0001224608) (Issuer)

      5/9/25 4:15:48 PM ET
      $CNO
      Accident &Health Insurance
      Finance
    • Director Foss David B was granted 4,378 units of Common Stock, increasing direct ownership by 10% to 49,151 units (SEC Form 4)

      4 - CNO Financial Group, Inc. (0001224608) (Issuer)

      5/9/25 4:14:28 PM ET
      $CNO
      Accident &Health Insurance
      Finance